Executive Summary Multiple-of-Medicare (“MoM”) repricing is a popular and common cost containment strategy used by many plans and repricing companies for dialysis claims repricing. Renalogic has intentionally chosen to stay away from MoM methods because of the high risk of…
The first appellate court decision in the DaVita Medicare Secondary Payor Act (“MSPA”) cases has come down. This decision, in DaVita v. Marietta Hospital, came down in DaVita’s favor and is probably taking a lot of people by surprise. The…
The Latest Development in Dialysis Carves in Pacific Northwest Dialysis In recent years the Pacific Northwest has been the venue for repeated disputes between the large dialysis organizations (“LDOs”) Fresenius and DaVita and payors trying to manage very high LDO…
Check your Kidney Profile or GFR Levels Kidney disease is often called the “silent killer.” More than 37 million American adults have Chronic Kidney Disease (CKD), yet 90 percent of people are not aware because they do not have symptoms.…
Many people do not realize that COVID-19 can affect more than a patient’s lungs. As more and more research on the affects of COVID-19 disseminates, we are finding out that the disease also has the potential to cause long term…
The central mission of Renalogic has always been to drive positive change for kidney disease and help members thrive while living with chronic conditions. These values hold even more now with our member’s lives so significantly impacted by the COVID-19…
Health Benefits Risk Management at the Intersection of Monopoly and Intensive Regulation The dialysis sector is an intensified microcosm of the American health care system, and that’s bad for self-insured plans in particular. On the one hand, the dialysis marketplace…
Treatment costs for chronic kidney disease (CKD) and end-stage renal disease (ESRD) are high and rising dramatically, putting self-funded health plans at risk. Meanwhile, most health plan members with moderate kidney damage are unaware they have it until it has…
All Rights Reserved 2021
